"We feel privileged to be among a select group of biotech companies showcasing our technologies to an elite group of interested investment professionals as well as senior executives from our industry sector," stated Dr. McNally.
About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1. GeoVax AIDS vaccines also may be effective as a therapeutic treatment for people already infected with the HIV-1 virus.
GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet
Robinson, Senior V.P. of Research and Development, through a collaboration of
GeoVax AIDS vaccines have moved forward in human clinical trials conducted
by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The
HVTN, funded through a cooperative agreement with the National Institutes of
Health (NIH), is the largest worldwide clinical trials program dedicated to
the development and testing of AIDS vaccines. Preclinical work enabling
evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID,
|SOURCE GeoVax Labs, Inc.|
Copyright©2009 PR Newswire.
All rights reserved